New approaches for treatment of diabetic nephropathy: The endothelium as a target for drug discovery

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 5, 2001, Pages 539-545

  Saxena, Uday ^a   Timmer, Richard T ^a   Pillarisetti, Sivaram ^a  

^a Reddy US Therapeutics   (United States)

Author keywords

Advanced glycation end products; Endothelium; Hyperinsulinaemia; IL 6; Nephropathy

Indexed keywords

EID: 33747587262     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.5.5.539     Document Type: Review

References (54)

1. KIKKAWA R, TOGAWA M, ISONO M, ISSHIKI K, HANEDA M: Mechanism of the progression of diabetic nephropathy to renal failure. Kidney Int. Suppl. (1997) 62:S39-40.
2. MCLAUGHLIN K, JARDINE AG: Clinical management of diabetic nephropathy. Diabetes Obes. Metab. (1999) 1(6):307-315.
3. MARCANTONI C, ORTALDA V, LUPO A, MASCHIO G: Progression of renal failure in diabetic nephropathy. Nephrol. Dial. Transplant (1998) 13(Suppl. 8):16-19.
4. THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. (1995) 47(6): 1703-20.
5. CROFFORD OB: Diabetes control and complications. Ann. Rev. Med. (1995) 46:267-279.
6. STEFFES MW: Glycemic control and the initiation and progression of the complications of diabetes mellitus. Kidney Int. Suppl. (1997) 63:S36-39.
7. THOMAS W, SHEN Y, MOLITCH ME, STEFFES MW: Rise in albuminuria and blood pressure in patients who progressed to diabetic nephropathy in the Diabetes Control and Complications Trial. J. Am. Soc. Nephrol. (2001) 12(2):333-340.
8. KLEIN R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care (1995) 18(2):258-68.
9. NISHIKAWA T, EDELSTEIN D, DU XL et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature (2000) 404:787-790.
10. GREENE DA, SIMA AA, LATTIMER SA et al.: Sorbitol, phosphoinositides and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med. (1987) 316:599-606.
11. THOMAS TP, PORCELLATI F, KATO K, STEVENS MJ, SHERMAN WR, GREENE DA: Effects of glucose on sorbitol pathway activation, cellular redox and metabolism of myo-inositol, phosphoinositide and diacylglycerol in cultured human retinal pigment epithelial cells. J. Clin. Invest. (1994) 93(6):2718-2724.
12. XIA P, INOGUCHI T, KERN TS, ENGERMAN RL, OATES PJ, KING GL: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes (1994) 43:1122-1129.
13. KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47(6):859-866.
14. ISHII H et al.: Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science (1996) 272:728-731.
15. BROWNLEE M: Advanced glycosylation in diabetes and aging. Ann. Rev. Med. (1995) 46:223-234.
16. CHEN S, COHEN MP, ZIYADEH FN: Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int. (2000) 58(Suppl. 77):S40-44.
17. SCHMIDT AM, YAN SD, WAUTIER JL, STERN D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. (1999) 84(5):489-497.
18. WANG MX, WALKER RG, KINCAID-SMITH P: Clinicopathologic associations of anti-endothelial cell antibodies in immunoglobulin A nephropathy and lupus nephritis. Am. J. Kidney Dis. (1993) 22(3):378-386.
19. KATZ SM, SCHWARTZ AB, BREZIN J: Glomerular endothelial endocytosis of subendothelial electron dense deposits. Hum. Pathol. (1980) 11(6):658-666.
20. VAN DE KAR NC, MONNENS LA, KARMALI MA, VAN HINSBERGH VW: Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood(1992) 80(11):2755-2764.
21. LAURENCE J, MITRA D: Apoptosis of microvascular endothelial cells in die pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome. Semin. Hematol. (1997) 34(2):98-105.
22. GARTNER HV, SAMMOUN A, WEHRMANN M, GROSSMANN T, JUNGHANS R, WEIHING C: Preeclamptic nephropathy - an endothelial lesion. A morphological study with a review of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. (1998) 77(1):11-27.
23. MATTEI P, VIRDIS A, GHIADONI L, TADDEI S, SALVETTI A: Endothelial function in hypertension. J. Nephrol. (1997) 10(4):192-197.
24. HOSHINO J, SAKAMAKI T, NAKAMURA T et al.: Exaggerated vascular response due to endothelial dysfunction and role of the renin-angiotensin system at early stage of renal hypertension in rats. Circ. Res. (1994) 74(1):130-138.
25. SAVAGE CO: The biology of the glomerulus: endothelial cells. Kidney Int. (1994) 45(2):314-319.
26. INAGAMI T, NARUSE M, HOOVER R: Endothelium as an endocrine organ. Ann. Rev. Physiol. (1995) 57:171-189.
27. BECKER RC: Seminars in thrombosis, thrombolysis and vascular biology. 1. The vascular endothelium. Cardiology (1991) 78(1):13-22.
28. KIRKPATRICK CJ, WAGNER M, HERMANNS I et al.: Physiology and cell biology of the endothelium: a dynamic interface for cell communication. Int. J. Microcirc. Clin. Exp. (1997) 17(5):231-240.
29. DANNE T, SPIRO MJ, SPIRO RG: Effect of high glucose on Type IV collagen production by cultured glomerular epithelial, endothelial and mesangial cells. Diabetes (1993) 42(1):170-177.
30. CHAKRAVARTHY U, HAYES RG, STITT AW, MCAULEY E, ARCHER DB: Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes (1998) 47(6):945-952.
31. GINSBERG HN: Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes (1996) 45(Suppl. 3):S27-30.
32. BERLINER J, LEITlNGER N, WATSON A, HUBER J, FOGELMAN A, NAVAB M: Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost. (1997) 78(1):195-199.
33. REAVEN PD, WITZTUM JL: Oxidized low density lipoproteins in atherogenesis: role of dietary modification. Ann. Rev. Nutr. (1996) 16:51-71.
34. DRUEKE TB, KHOA TN, MASSY ZA, WITKO-SARSAT V, LACOUR B, DESCAMPS-LATSCHA B: Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int. (2001) 59(Suppl. 78):S114-119.
35. MICHIAKI KUBO, YUTAKA KIYOHARA, ISAO KATO et al.: Effect of hyperinsulinemia on renal function in a general Japanese population. The Hisayama study Kidney International 55(Issue 6)(1999).
36. FESTA A, D'AGOSTINO R, HOWARD G, MYKKANEN L, TRACY RP, HAFFNER SM: Inflammation and microalbuminuria in nondiabetic and Type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int. (2000) 58(4):1703-1710.
37. FESTA A, D'AGOSTINO R Jr., HOWARD G, MYKKANEN L, TRACY RP, HAFFNER SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation (2000) 102(1):42-47.
38. YAMAMOTO Y, KATO I, DOI T et al.: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. (2001) 108(2):261-268.
39. SHARMA K, MCGOWAN TA: TGF-beta in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev. (2000) 11(1-2):115-123.
40. ZIYADEH FN, HUFFMAN BB, HAN DC et al.: Long-term prevention of renal insufficiency, excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA (2000) 97(14):8015-8020.
41. CHEN S, COHEN MP, LAUTENSLAGER GT, SHEARMAN CW, ZIYADEH FN: Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int. (2001) 59(2):673-681.
42. CAHOON S, WINES A, SAXENA U, PILLARISETTI S: Synergistic induction of IL-6 by diabetic stimuli - an initiating event in diabetic nephropathy? Diabetes (2001) Abstract.
43. EITNER F, WESTERHUIS R, BURG M et al.: Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int. (1997) 51(1):69-78.
44. GOLDBERG HJ, SCHOLEY J, FANTUS IG: Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes (2000) 49(5):863-871.
45. KOLM-LITTY V, SAUER U, NERLICH A, LEHMANN R, SCHLEICHER ED: High glucose-induced transforming growth factor betal production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. (1998) 101(1):160-169.
46. YANG X, SU K, ROOS MD, CHANG Q, PATERSON AJ, KUDLOW JE: O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc. Natl. Acad. Sci. USA (2001) 98(12):6611-6616.
47. DU XL, EDELSTEIN D. ROSSETTI L et al.: Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosyktion. Proc. Natl. Acad. Sci. USA (2000) 97(22):12222-12226.
48. CHEN YQ, SU M, WALIA RR, HAO Q, COVINGTON JW, VAUGHAN DE: Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J. Biol. Chem. (1998) 273(14):8225-8231.
49. PAKA S, KAKO Y, PILLARISETTI S: Distinct effects of glucose and glucosamine on endothelial and smooth muscle cells. Diabetes (2000) Abstract.
50. OTTENSMEYER FP, BENIAC DR, LUO RZ, YIP CC: Mechanism of transmembrane signaling: insulin binding and the insulin receptor. Biochemistry (2000) 39(40):12103-12112.
51. ROMASHKOVA JA, MAKAROV SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signaling. Nature (1999) 401(6748):86-90.
52. OZES ON, MAYO LD, GUSTIN JA, PFEFFER SR, PFEFFER LM, DONNER DB: NF-kappaB activation by tumor necrosis factor requires the Akt serine-threonine kinase. Nature (1999) 401(6748):82-85.
53. BERTRAND F, PHILIPPE C, ANTOINE PJ et al.: Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway. J. Biol. Chem. (1995) 270(41):24435-24441.
54. FORBES JM, SOULIS T, THALLAS V et al.: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia (2001) 44(1):108-114.